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A B S T R A C T
Weeks or months following Campylobacter infection, a small proportion of infected individuals develop
Guillain–Barre´ syndrome (GBS) or reactive arthritis (ReA). Stool culture for Campylobacter is often
negative in these patients, and serology is therefore the method of choice for diagnosing a recent
infection with Campylobacter. This study developed a capture ELISA system to detect anti-Campylobacter
IgA and IgM antibodies indicative of a recent infection. The sensitivity of the assay was 82.0% in
uncomplicated Campylobacter enteritis patients, 96.2% in GBS patients who were culture-positive for
Campylobacter, and 93.1% in culture-positive ReA patients, with a specificity of 93.0%. The assay allows
identification of Campylobacter infection in patients with post-infectious neurological and rheumatolog-
ical complications.
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I N T R O D U C T I O N
Campylobacter spp. are the most frequently iden-
tified bacterial cause of diarrhoea in industrialised
countries [1,2]. In the weeks or months following
infection with Campylobacter, a small proportion
of patients develop post-infectious sequelae. Guil-
lain–Barre´ syndrome (GBS), an immune-mediated
neuropathy, develops in 0.1–0.5% of patients
infected with Campylobacter [3]. Reactive arthritis
(ReA), a sterile immune-mediated inflammation
of joints, occurs more frequently after enteric
infections. Depending on the study population,
5–15% of patients with enteritis caused by
Campylobacter develop joint symptoms [4–6].
The symptoms of patients with neurological
and rheumatological disease may be caused by
mechanisms other than post-infectious immune
derangement, and identification of potential trig-
gering infections is therefore important in these
patient groups. However, in most cases of GBS
and ReA, a bacterial stool culture is either not
performed or the culture is negative. Possible
reasons for a negative result include the length of
time since the gastrointestinal episode, and anti-
biotic treatment of diarrhoeal symptoms [6]. In
addition, the triggering Campylobacter infection
may have been asymptomatic, and therefore
the physician may not have been prompted to
perform stool cultures.
In the absence of positive cultures, the method
of choice for determining a recent Campylobacter
infection is serology. A wide range of methods
for demonstration of antibodies against Campylo-
bacter exist, including complement fixation,
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western blots and ELISAs [7–9]. ELISA-based
methods are the most convenient because of
their superior sensitivity compared to comple-
ment fixation, as well as their potential for
standardisation [10]. Crude protein fractions
are often used in ELISAs, but one report has
described the use of purified recombinant
Campylobacter proteins [11]. However, most
ELISAs described in the literature have not been
validated for their use in determining Campylo-
bacter infections in cases of GBS and ReA, or
have not been validated extensively [4,12,13].
The present study developed an antibody-
capture ELISA for detection of IgA and IgM
antibodies against Campylobacter antigens, in com-
bination with an indirect ELISA for detection of
IgG antibodies. A capture ELISA for determining
IgA and IgM reactivity was chosen because, with
an indirect ELISA method, high levels of IgG may
occupy binding sites in the ELISA plate, thereby
lowering the measured IgA and IgM response.
The capture ELISA enables the fraction of serum
IgA or IgM directed against Campylobacter to be
measured, unbiased by the presence of Campylo-
bacter-specific IgG or rheumatoid factors. For
optimal validation of the assay, a large number
of sera from patients with uncomplicated Campylo-
bacter enteritis were used, as well as sera from
GBS and ReA patients with a culture-confirmed
infection with Campylobacter. In addition, the new
ELISA was compared with a well-validated assay
that has been described previously and is used
routinely [14].
M A T E R I A L S A N D M E T H O D S
Sera
Sera were obtained from patients in Denmark and The
Netherlands. Pre-treatment sera were available from 26
patients with GBS or Miller Fisher syndrome (a subgroup
of GBS), of whom 25 had a culture-confirmed infection with
Campylobacter jejuni, and one had a positive stool culture for
Campylobacter upsaliensis. Some of these patients have been
described in a previous study [15]. Twenty-nine sera from
patients with ReA were available for study, derived partly
from a previous study [6]. All ReA patients had a culture-
confirmed infection with C. jejuni. Sera from 162 patients
with culture-confirmed uncomplicated Campylobacter enteritis
were also included in the study; 145 patients were infected
with C. jejuni, 13 with Campylobacter coli and four with an
unspeciated Campylobacter isolate. For the patients with
uncomplicated enteritis, the time at which serum was
sampled ranged from 9 days before a positive culture to
155 days after a positive culture. Twenty-eight sera from
culture-positive non-typhoidal Salmonella patients and 20
sera from serologically positive Yersinia enterocolitica patients
were used as diarrhoeal controls. To investigate antibodies
that were cross-reactive with other microorganisms, sera
from 20 patients with serological evidence of Legionella
pneumophila infection and 20 patients with Helicobacter pylori
infection were used. Finally, sera from 482 healthy controls,
derived partly from the PIENTER project [16], were includ-
ed.
ELISAs
Preparation of antigens. The Campylobacter strain used for the
assay was C. jejuni SSDZ-01, Penner serotype O:4,64 (typed by
L. Price, LCDC Winnipeg, Canada). Microaerobic growth in
blood agar plates for 48 h was used for preparation of
Campylobacter protein stock for coating and peroxidase
labelling. The bacteria were harvested in saline and extrac-
ted with acid glycine, yielding a mixture of (glyco)proteins
that included flagellar antigens [17,18]. In brief, cells were
harvested in phosphate-buffered saline pH 7.4 (PBS), centri-
fuged for 20 min at 3000 g, and washed with sterile distilled
water. The cell pellet was suspended in 0.2 M glycine
hydrochloride buffer (pH 2.2) at a concentration of 1 g of
biomass in 5 mL of buffer. Antigen extraction was per-
formed by incubation overnight at 4C with continuous
rotation, followed by sonication (three bursts of 30 s), and
centrifugation at 12 000 g for 20 min at 4C. The supernatant
was re-extracted with acid glycine. For indirect ELISA (IgG),
the (glyco)protein extract was suspended in PBS containing
glycerol 50% v ⁄v. For detection of IgA and IgM against
Campylobacter, the antigen was labelled with peroxidase, as
described previously with slight modifications [19]. Glycine-
extracted antigen (5 mg) was dissolved in 2.5 mL of 0.1 M
sodium carbonate buffer. Horseradish peroxidase (7 mg)
(Sigma, Zwijndrecht, The Netherlands) was dissolved in
1.75 mL of distilled water and oxidised by adding 350 lL of
0.2 M NaIO4. This solution was dialysed against 0.001 M
sodium acetate buffer for 4 h. The antigen and peroxidase
solutions were mixed and incubated for 2 h at room
temperature with stirring. The conjugates were stabilised
by adding 175 lL of Na(BH4) solution, and were then
dialysed overnight against 0.1 M Tris buffer, pH 8.0. Conju-
gated Campylobacter antigens were stored at )20C in 0.05 M
Tris buffer, pH 8.0, containing glycerol 50% v ⁄v. Optimal
dilutions of conjugated antigens were determined using
block titration.
IgA and IgM ELISAs. Microtitre plates (Immulon; Greiner, Al-
phen a ⁄d Rijn, The Netherlands) were coated with rabbit
anti-human IgA or IgM (Dako, Glostrup, Denmark). Coated
plates were stored at )20C until use. Sera were diluted
1:100 in Tris bactopeptone buffer (0.01 M Tris-HCl, pH 8.0,
neutralised bacteriological peptone (Oxoid, Basingstoke, UK)
5% v ⁄v, Tween-20 0.25% v ⁄v) containing an Escherichia coli
J5 acid glycine extract (5% v ⁄v) to minimise aspecific
reactivity, and were then incubated at 37C for 1 h. Follow-
ing incubation, the plates were washed with PBS and
incubated with peroxidase-labelled Campylobacter antigen.
After incubation for 1 h at 37C, the plates were washed and
3,3¢,5,5¢-tetramethylbenzidine substrate solution (Perbio,
Rockford, IL, USA) was added. The reaction was terminated
after 30 min by adding H2SO4 stop solution and the plates
were read at a wavelength of 450 nm.
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IgG ELISA. For indirect IgG ELISA, microtitre plates were
coated with unlabelled Campylobacter antigen in 0.1 M
NH4HCO3 buffer. The antigen concentration was determined
by block titration and was found to be optimal at a concen-
tration of 3 mg ⁄L. Plates were stored at )20C until use.
Diluted sera were incubated at 37C for 1 h. Following
incubation, the plates were washed with PBS and incubated
with peroxidase-labelled goat anti-human IgG. Further wash-
ing and development was performed as described above.
All sera were stored at )20C until use and were tested in
duplicate. Each plate included a positive control, a negative
control and a reference serum. The results were expressed as a
ratio, calculated by dividing the mean of the duplicate OD
values by the OD value of the reference serum.
Danish ELISA. The Danish Campylobacter ELISA was
performed as described by Strid et al. [14].
Statistical analysis
Statistical analysis was performed using SPSS for Windows
v.11.5 (SPSS Inc., Chicago, Il, USA). Optimal cut-off IgA, IgM
and IgG ratios were determined using receiver operator
characteristic (ROC) curves. Quantitative differences among
groups were tested non-parametrically with the Mann–Whit-
ney U-test, and differences among fractions were tested with
the chi-square test; p values <0.05 were considered to be
significant. Correlation among ELISAs was calculated using
kappa values, and linearity among the assays was tested by
calculating the Spearman correlation coefficient.
R E S U L T S
Figs 1 and 2 show the ROC curves and scatter-
plots used to determine the cut-offs for positivity.
For the ROC curves, 162 patients with uncompli-
cated Campylobacter enteritis were used as posit-
ive cases and 482 healthy controls were used as
negative controls. The area under the curve was
0.92 for IgA, 0.91 for IgM and 0.89 for IgG. With
an arbitrary specificity level of 95%, the cut-off
ratios for IgA, IgM and IgG were 0.6, 1.0 and 10.0,
respectively (Fig. 2). The same cut-off values were
found when sera were analysed separately, based
on country of origin, thereby indicating the
stability of the test in different geographical areas.
Using these cut-off ratios, the specificity of the
assay could be determined in various patient
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Fig. 1. Receiver operator characteristic (ROC) curves of the Campylobacter ELISA. ROC curves are based on the values
obtained for uncomplicated Campylobacter enteritis patients (n = 162) and healthy controls (n = 482). (a) IgA. (b) IgM. (c)
IgG.
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Fig. 2. Scatterplots of ratios for (a)
IgA, (b) IgM and (c) IgG in the
Campylobacter ELISA for various
patient groups. Each dot represents
one serum sample. Bars indicate the
median ratio for each group. Dotted
lines indicate the proposed cut-off
values. GBS ⁄MFS, Guillain–Bar-
re´ ⁄Miller Fisher syndrome; ReA,
reactive arthritis.
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groups. In patients with diarrhoea caused by
Salmonella or Yersinia, four (8.3%) of 48 patients
had IgA and ⁄ or IgM antibodies against Campylo-
bacter (Table 1).
To investigate possible cross-reactivity of
anti-Campylobacter antibodies with other patho-
gens, sera from 40 patients with a serologically
determined infection with H. pylori or L. pneu-
mophila were also tested. In this group, four
patients had IgA and ⁄ or IgM antibodies against
Campylobacter. This proportion is in the same
range as the proportion of positive patients
in the healthy control group (7.0%; Table 1).
These data indicate that antibodies against other
pathogens do not influence the test results
significantly.
The sensitivity of the assay varied according to
the time of serum sampling relative to the first
positive culture (Table 2). The interval between
positive culture and serum sampling was used,
rather than the time between the onset of diar-
rhoeal symptoms and serum sampling, because
the latter data were not available for all patients.
However, the available data indicated that the
median number of days from onset of symptoms
to first positive culture was 6 days.
The number of IgA- and ⁄ or IgM-positive
uncomplicated Campylobacter enteritis patients
was lowest in the phase before positive culture,
although still 58.3%. The sensitivity of determin-
ing IgA and ⁄ or IgM antibodies was highest
(c. 80%) during the first 70 days following a
positive culture. These characteristics make this
test very suitable for diagnosing recent Campylo-
bacter infections in GBS and ReA patients, as these
patients typically present several weeks or
months following infection.
The ELISA was capable of detecting recent
infections with all Campylobacter spp. tested,
although the sensitivity for detection of IgA
and ⁄ or IgM was reduced for patients infected
with C. coli as compared with those infected with
C. jejuni (53.8% vs. 82.8%, p 0.012). There were
very few infections with subspecies other than
C. jejuni ⁄ coli. Of the four patients with uncompli-
cated enteritis caused by an unspeciated Campylo-
bacter isolate, two had elevated IgA or IgM
levels in combination with high levels of IgG.
One GBS patient with a C. upsaliensis infection
was positive for IgA, negative for IgM, and
positive for IgG. These observations indicate that
the assay has the potential to detect infections
Table 1. Sensitivity of the Campylo-
bacter ELISA in various groups
Group No. of sera
No. of positive results (% sensitivity)
IgA IgM IgG
IgA and ⁄
or IgM
IgA and ⁄ or
IgM and ⁄
or IgG
Guillain–Barre´ syndrome
(Campylobacter culture-confirmed)
26 24 (92.3) 18 (69.2) 25 (96.2) 25 (96.2) 26 (100)
Reactive arthritis (Campylobacter
culture-confirmed)
29 15 (71.7) 25 (86.2) 20 (69.0) 27 (93.1) 28 (96.6)
Uncomplicated Campylobacter
enteritis (culture-confirmed)
162 98 (60.5) 105 (64.8) 105 (64.8) 129 (79.6) 142 (87.7)
Diarrhoea controlsa 48 4 (8.3) 1 (2.1) 4 (8.3) 4 (8.3) 6 (12.5)
Cross-reactivity controlsb 40 3 (7.5) 1 (2.5) 4 (10.0) 4 (10.0) 7 (17.5)
Healthy controls 482 14 (2.9) 21 (4.4) 20 (4.1) 34 (7.0) 46 (9.6)
aSera from patients with Salmonella or Yersinia enterocolitica infection.
bSera from patients with Helicobacter pylori or Legionella pneumophila infection.
Table 2. Sensitivity of the Campylo-
bacter ELISA in patients with
uncomplicated Campylobacter enter-
itis in relation to the time of serum
sampling
Time of serum sampling
after first positive culture (days)
No. of
sera
No. of positive results (% sensitivity)
IgA IgM IgG
IgA and ⁄
or IgM
IgA and ⁄ or
IgM and ⁄ or IgG
)9 to )1 12 6 (50.0) 6 (50.0) 3 (25.0) 7 (58.3) 7 (58.4)
0–14 37 26 (70.2) 26 (70.2) 21 (56.7) 31 (83.8) 32 (86.5)
15–28 33 20 (60.6) 25 (75.8) 26 (68.4) 29 (87.9) 32 (97.0)
29–42 17 8 (47.0) 8 (47.0) 10 (58.8) 12 (71.6) 14 (82.4)
43–56 8 5 (62.5) 5 (62.5) 7 (87.5) 6 (75.0) 8 (100)
57–70 3 1 (33.3) 1 (33.3) 2 (66.7) 2 (66.7) 2 (66.7)
‡71 5 3 (60.0) 1 (20.0) 3 (60.0) 3 (60.0) 3 (60.0)
Totala 115
aInformation concerning the time of serum sampling was available for 115 ⁄ 162 patients.
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with species other than C. jejuni, albeit with
reduced sensitivity.
The age of the patients was related to the
immune response to Campylobacter. The propor-
tion of IgG-positive patients with an uncompli-
cated Campylobacter enteritis increased with age
(p 0.005 for trend), whereas the reverse was found
for IgM (not significant; Table 3). In addition,
older patients had a positive test result for IgA
more frequently.
The sensitivity of the ELISA with sera from
Campylobacter culture-positive GBS and ReA
patients is shown in Table 1. For both post-
infectious patient groups, the sensitivity, based
on IgA and ⁄ or IgM positivity, was 96.2% and
93.2%, respectively. Inclusion of IgG seropositiv-
ity as a criterion for recent infection yielded only a
slight increase in sensitivity.
Interestingly, quantitative differences were
observed between patients with uncomplicated
Campylobacter enteritis and patients with post-
infectious complications. When the antibody
response for GBS patients and enteritis patients
with a sampling date of 4–50 days was compared,
i.e., roughly the same period during which a GBS
patient would have been sampled, the mean IgA,
IgM and IgG levels were higher in GBS patients
than in patients with an uncomplicated enteritis
(see also Fig. 2). This was statistically significant
for IgA (p 0.005; Mann–Whitney U-test). The
picture was less clear for ReA patients, who had
a lower IgA response than patients with uncom-
plicated enteritis, although this was not signifi-
cant. However, the IgM response in ReA patients
was elevated (p 0.026; Mann–Whitney U-test),
whereas there was no difference in the IgG
response.
The new ELISA was compared with an ELISA
developed previously in Denmark [14]. Sera from
47 patients with culture-confirmed Campylobacter
infection and 30 healthy controls were tested
blind in Amsterdam and Copenhagen. Although
the new ELISA used a capture method for
determining IgA and IgM antibodies, while the
Danish ELISA used a direct ELISA method, the
two tests showed good agreement. For IgA and
IgM, kappa values were 0.594 and 0.775, respect-
ively, with Spearman correlation coefficients of
0.783 (IgA) and 0.758 (IgM). Comparison of the
IgG ELISAs yielded comparable results (kappa
0.732, Spearman 0.859). The combination of IgA
and ⁄ or IgM had a slightly higher kappa value of
0.783. For all antibody classes, the new ELISA
produced slightly higher positive ⁄negative ratios
than the Danish ELISA, indicating that the anti-
gen used in the new ELISA may be more specific.
However, with the chosen cut-off values, the
Danish ELISA was slightly more sensitive than
the new ELISA, with a sensitivity of 100% for
detecting a previous Campylobacter infection in
culture-positive ReA patients.
D I S C U S S I O N
This report describes the development of a highly
sensitive and specific ELISA for the detection of
preceding Campylobacter infections in various
patient groups, including GBS and ReA patients.
Cohorts of Campylobacter culture-positive GBS
and ReA patients were used as reference stand-
ards to determine the sensitivity of the assay in
these patient groups. Few studies have used such
well-described patient groups to validate similar
tests. Based on positivity for IgA and ⁄ or IgM, the
sensitivity of the assay was very high in both post-
infection patient groups (96.2% in GBS patients
and 93.1% in ReA patients). A well-validated
assay for detection of Campylobacter infections in
GBS patients was described by Koga et al. [13],
who used an elevated IgG anti-Campylobacter titre
Table 3. Sensitivity of the Campylo-
bacter ELISA in patients with
uncomplicated Campylobacter enter-
itis in relation to age Age (years) No. of sera
No. of positive results (% sensitivity)
IgA IgM IgG IgA and ⁄ or IgM
IgA and ⁄ or IgM
and ⁄ or IgG
0–10 7 4 (57.1) 4 (57.1) 3 (42.9) 4 (57.1) 4 (57.1)
11–20 8 5 (62.5) 6 (75.0) 1 (12.5) 7 (87.5) 7 (87.5)
21–30 33 16 (48.4) 24 (72.7) 17 (51.5) 27 (81.8) 29 (87.9)
31–40 23 16 (69.6) 19 (82.6) 19 (82.6) 21 (91.3) 22 (95.7)
41–50 21 14 (66.7) 11 (52.4) 13 (61.9) 16 (76.2) 18 (85.7)
51–60 28 18 (64.3) 17 (60.7) 22 (78.6) 21 (75.0) 26 (92.9)
‡61 22 16 (72.7) 12 (54.5) 15 (68.2) 18 (81.2) 18 (81.2)
Totala 142
aInformation concerning age was available for 142 ⁄ 162 patients.
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as evidence of recent infection. This assay had
a sensitivity of 82% for detecting a preceding
infection in Campylobacter culture-positive GBS
patients. Mishu et al. [20] used sera from 17
patients with uncomplicated enteritis and 39
controls, and reported a sensitivity in cases of
uncomplicated enteritis of 65%, using the pro-
posed criterion for positivity of an OD ratio ‡2
in at least two isotypes. A further report has
described the use of recombinant Campylobacter
antigens in an IgA ⁄ IgG ELISA to detect recent
infections with Campylobacter in a group of GBS
patients who were unselected with respect to
preceding infection [21]. Surprisingly, the assay
indicated a preceding Campylobacter infection in
80% of GBS patients, but no information concern-
ing culture results for this group was available.
The assay described by Strid et al. [14] has also
been used for detection of Campylobacter seropo-
sitivity in ReA patients, with a sensitivity in
Campylobacter culture-positive ReA patients of
100%. The antigen used in the new ELISA seemed
to be more specific than that used in the Danish
ELISA, while the latter was slightly more sensi-
tive. Fortunately, despite the technical differences,
the high kappa values indicate a high level of
agreement between the two ELISAs, which allows
the comparison of studies using either test.
The present study used the presence of either
IgA or IgM against Campylobacter as evidence of a
recent infection. IgG was not used as a criterion,
because high IgG reactivity against Campylobacter
can persist for months or years after infection
[9,14,18,22,23]. The target populations for the
study were GBS and ReA patients, typically
presenting several weeks following Campylobacter
infection. A patient possessing only IgG antibod-
ies could, theoretically, have been infected with
Campylobacter at least 1 year previously, unrelated
to the neurological or rheumatological symptoms
[24]. However, some recent infections will be
missed, because occasional individuals mount an
IgG response only following infection with
Campylobacter. Other reports advocate the use of
seropositivity for two or more isotypes as a
criterion for seropositivity in GBS and ReA
patients [12,25]. In the present cohort of patients,
those aged <20 years often did not have an
elevated IgG response, despite elevated IgA
and ⁄ or IgM levels. Furthermore, fewer than half
of the uncomplicated enteritis patients had
elevated levels of both IgA and IgM. Therefore,
use of seropositivity for two or more isotypes as a
criterion for diagnosis of a recent infection with
Campylobacter could result in many false-negative
results, especially in young patients. The presence
of an elevated titre of either IgA or IgM is
sufficient to diagnose a recent Campylobacter
infection.
The present study confirmed previous reports
that demonstrated the high sensitivity of ELISA
methods, in comparison with other methods
such as complement binding, for detection of
recent Campylobacter infections [10,11,14]. Com-
mercially available ELISA kits for detection of
anti-Campylobacter antibodies are available, but
no validation studies have been published. With
the availability of easy-to-perform in-house
assays, the use of methods with far less sensi-
tivity (e.g., complement binding) should be
discouraged.
The new assay described in the present study
was evaluated using sera from patients with
documented infections with other diarrhoeal
pathogens, as well as pathogens that have been
associated with possible cross-reactions in
Campylobacter assays [22]. In this group of
patients, the proportion of positive sera, based
on an elevated IgA and ⁄ or IgM level, was
comparable to that found among healthy indi-
viduals. Analysis of these cases showed that
many of these individuals also had an elevated
IgG level, indicating that the positive test was
caused by a recent infection with Campylobacter
and not by a false-positive reaction in the assay.
The sensitivity of the new assay was highest in
the first 2 months following infection. This win-
dow matches the period of presentation with
post-infectious complications, which makes the
assay perfectly suited to detect preceding
Campylobacter infections as triggers for immune-
mediated disease [6,26]. However, the sensitivity
of the ELISA was lower for patients infected
with C. coli than for patients infected with
C. jejuni. For other Campylobacter spp., the num-
ber of patients was too low for conclusions to be
drawn, although seropositivity in a single GBS
patient infected with C. upsaliensis indicates that
the assay has the potential to detect infections
with species other than C. jejuni and C. coli.
As described in previous studies, the age at
which infection is acquired was found to influ-
ence the strength of the immune response to
Campylobacter [14,24]. The strength of the IgM
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response decreased in higher-age cohorts,
although this was not significant in the present
cohort of patients. In addition, a profound effect
of age on the strength of the IgG response was
found. Only 25% of patients aged <21 years had a
high IgG response. The remaining patients in this
age group had detectable anti-Campylobacter IgG
reactivity, but the ratio in these sera was <10, and
was therefore too low to match the criterion for a
recent infection. This observation may be ex-
plained by a booster effect of repeated Campylo-
bacter infection during childhood and
adolescence. Surprisingly, an increasing propor-
tion of IgA-positive patients was found in the
higher-age cohorts. This has not been observed in
previous studies, but might be explained by the
capture ELISA system used. With this system,
serum IgA is bound to the ELISA plate, and anti-
Campylobacter reactivity is detected with peroxi-
dase-labelled Campylobacter antigen. Therefore,
the present assay measures the proportion of
IgA in serum that is directed against Campylo-
bacter. In contrast, with an indirect ELISA method,
anti-Campylobacter IgA and IgM compete with IgG
for binding sites. When high levels of IgG are
present, as is the case in older patients, the IgA or
IgM levels may be underestimated by indirect
ELISA methods.
With respect to the pathogenesis of post-infec-
tious complications of Campylobacter, the finding
that the antibody response in GBS patients was
stronger than that in uncomplicated enteritis
patients warrants further investigation. It is
known that GBS patients have a stronger anti-
body response against lipooligosaccharides of
Campylobacter [15]. These anti-lipooligosaccharide
antibodies cross-react with human nervous tissue,
thereby invoking immunological damage and
nerve dysfunction [27]. The enhanced reactivity
towards glycine-extracted antigens, proteins and
glycoproteins indicates that GBS patients have a
generally hyper-reactive immune response when
challenged with Campylobacter.
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